Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McGill University

$133,334.00

DNA cages as a platform for efficient and selective delivery of therapeutics into tumor cells

FY 2014-15

Summary
General drug cytotoxicity and drug resistance are major hurdles in traditional cancer therapies, stemming from thenonspecificdelivery of cancer therapeutics to normal and cancerous cells simultaneously. We aim to develop a new method fortargeted cancer therapy using non-toxic DNA cages and nanotubes. Length, diameter and composition of these DNA cagescan be tuned and modified, to generate delivery molecules that can accommodate a plethora of cargo molecules, includingcancer therapeutics.We have shown that DNA cages are able to accumulate in cancer cells, more specifically in drug resistant leukemia cells.We propose to encapsulate a wide range of cancer destroying molecules such as cytotoxic drugs, RNA molecules, and othercancer inhibiting agents.We propose that this novel class of cages made up of DNA bases, will evade the innate immune system, successfully andspecifically deliver novel and pre-existing cancer therapeutics to cancer cells without affecting normal cells.
Program
Collaborative Health Research Projects
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
446389-2013
Name nom
Sleiman, Hanadi
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2013
Award amount
133334
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
DNA cages as a platform for efficient and selective delivery of therapeutics into tumor cells
Keyword
NSERC
Application summary
General drug cytotoxicity and drug resistance are major hurdles in traditional cancer therapies, stemming from thenonspecificdelivery of cancer therapeutics to normal and cancerous cells simultaneously. We aim to develop a new method fortargeted cancer therapy using non-toxic DNA cages and nanotubes. Length, diameter and composition of these DNA cagescan be tuned and modified, to generate delivery molecules that can accommodate a plethora of cargo molecules, includingcancer therapeutics.We have shown that DNA cages are able to accumulate in cancer cells, more specifically in drug resistant leukemia cells.We propose to encapsulate a wide range of cancer destroying molecules such as cytotoxic drugs, RNA molecules, and othercancer inhibiting agents.We propose that this novel class of cages made up of DNA bases, will evade the innate immune system, successfully andspecifically deliver novel and pre-existing cancer therapeutics to cancer cells without affecting normal cells.
McGill University - $133,334 Grant (2014-15) | Canada Spends